NASDAQ: MDGLMadrigal Pharmaceuticals Inc Stock
$514.12+6.56 (+1.29%)
Updated Aug 5, 2026
MDGL Price
$514.12
Fair Value Price
$1,239.80
Market Cap
$11.88B
52 Week Low
$333.24
52 Week High
$615.00
P/E
-40.01x
P/B
22.68x
P/S
12.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.28B
Earnings
-$325.10M
Gross Margin
91.5%
Operating Margin
-22.87%
Profit Margin
-25.3%
Debt to Equity
1.38
Operating Cash Flow
-$198M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDGL Overview
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDGL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MDGL
Ranked#59 of 465
Ranked#59 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.75 | A | |
| $110.69 | A | |
| $8.11 | A |
Be the first to know about important MDGL news, forecast changes, insider trades & much more!
MDGL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDGL ($514.12) is undervalued by 58.53% relative to our estimate of its Fair Value price of $1,239.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MDGL ($514.12) is significantly undervalued by 58.53% relative to our estimate of its Fair Value price of $1,239.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDGL due diligence checks available for Premium users.
Valuation
MDGL fair value
Fair Value of MDGL stock based on Discounted Cash Flow (DCF)
Price
$514.12
Fair Value
$1,239.80
Undervalued by
58.53%
MDGL ($514.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGL ($514.12) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-40.01x
Industry
14.89x
Market
14.23x
MDGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
22.68x
Industry
5.31x
MDGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDGL's financial health
Profit margin
Revenue
$364.3M
Net Income
-$57.9M
Profit Margin
-15.9%
MDGL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MDGL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$720.9M
Debt to equity
1.38
MDGL's short-term assets ($1.20B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGL's short-term assets ($1.20B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$23.3M
Investing
$34.2M
Financing
$3.1M
MDGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDGL vs Biotech Stocks
Madrigal Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.